false
0001640266
0001640266
2025-09-02
2025-09-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): September 2, 2025
Voyager
Therapeutics, Inc.
(Exact name of
registrant as specified in its charter)
| Delaware |
|
001-37625 |
|
46-3003182 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
75 Hayden Avenue
Lexington,
Massachusetts |
|
02421 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s telephone number,
including area code (857) 259-5340
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
| Common
Stock, $0.001 par value |
VYGR |
Nasdaq
Global Select Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure.
Voyager Therapeutics, Inc. (the “Company”),
plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at Citi’s
2025 Biopharma Back to School Conference on September 2, 2025 at 4:00 p.m. ET.
A copy of the Presentation is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on
Form 8-K (including Item 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth
by specific reference in such a filing.
By providing the information in Item 7.01
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, the Company is not making an admission as to the materiality of any
information herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of more complete
information included in the Company’s filings with the SEC and other public announcements that the Company has made and may make
from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained
in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating
may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Voyager Therapeutics, Inc. Presentation September 2025 |
| 104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 2, 2025 |
VOYAGER THERAPEUTICS, INC. |
| |
|
| |
By: |
/s/ Nathan Jorgensen, Ph.D. |
| |
|
Nathan Jorgensen, Ph.D. |
| |
|
Chief Financial Officer |
| |
|
(Principal Financial and Accounting Officer) |
